510 related articles for article (PubMed ID: 19465233)
1. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial.
Rajamani K; Colman PG; Li LP; Best JD; Voysey M; D'Emden MC; Laakso M; Baker JR; Keech AC;
Lancet; 2009 May; 373(9677):1780-8. PubMed ID: 19465233
[TBL] [Abstract][Full Text] [Related]
2. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
[TBL] [Abstract][Full Text] [Related]
3. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.
Keech AC; Mitchell P; Summanen PA; O'Day J; Davis TM; Moffitt MS; Taskinen MR; Simes RJ; Tse D; Williamson E; Merrifield A; Laatikainen LT; d'Emden MC; Crimet DC; O'Connell RL; Colman PG;
Lancet; 2007 Nov; 370(9600):1687-97. PubMed ID: 17988728
[TBL] [Abstract][Full Text] [Related]
4. Fenofibrate and risk of minor amputations in diabetes.
Fazio S; Linton MF
Lancet; 2009 May; 373(9677):1740-1. PubMed ID: 19465214
[No Abstract] [Full Text] [Related]
5. Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study.
Waldman B; Ansquer JC; Sullivan DR; Jenkins AJ; McGill N; Buizen L; Davis TME; Best JD; Li L; Feher MD; Foucher C; Kesaniemi YA; Flack J; d'Emden MC; Scott RS; Hedley J; Gebski V; Keech AC;
Lancet Diabetes Endocrinol; 2018 Apr; 6(4):310-318. PubMed ID: 29496472
[TBL] [Abstract][Full Text] [Related]
6. Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Chan KH; O'Connell RL; Sullivan DR; Hoffmann LS; Rajamani K; Whiting M; Donoghoe MW; Vanhala M; Hamer A; Yu B; Stocker R; Ng MK; Keech AC;
Diabetologia; 2013 Apr; 56(4):724-36. PubMed ID: 23322233
[TBL] [Abstract][Full Text] [Related]
7. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
[TBL] [Abstract][Full Text] [Related]
8. How can we improve the management of vascular risk in type 2 diabetes: insights from FIELD.
Steiner G
Cardiovasc Drugs Ther; 2009 Oct; 23(5):403-8. PubMed ID: 19757004
[TBL] [Abstract][Full Text] [Related]
9. Effects of combination lipid therapy in type 2 diabetes mellitus.
; Ginsberg HN; Elam MB; Lovato LC; Crouse JR; Leiter LA; Linz P; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm RH; Ismail-Beigi F; Bigger JT; Goff DC; Cushman WC; Simons-Morton DG; Byington RP
N Engl J Med; 2010 Apr; 362(17):1563-74. PubMed ID: 20228404
[TBL] [Abstract][Full Text] [Related]
10. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
[TBL] [Abstract][Full Text] [Related]
11. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study.
Davis TM; Ting R; Best JD; Donoghoe MW; Drury PL; Sullivan DR; Jenkins AJ; O'Connell RL; Whiting MJ; Glasziou PP; Simes RJ; Kesäniemi YA; Gebski VJ; Scott RS; Keech AC;
Diabetologia; 2011 Feb; 54(2):280-90. PubMed ID: 21052978
[TBL] [Abstract][Full Text] [Related]
12. More clinical lessons from the FIELD study.
Fazio S
Cardiovasc Drugs Ther; 2009 Jun; 23(3):235-41. PubMed ID: 19160032
[TBL] [Abstract][Full Text] [Related]
13. Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial.
Scott R; Donoghoe M; Watts GF; O'Brien R; Pardy C; Taskinen MR; Davis TM; Colman PG; Manning P; Fulcher G; Keech AC;
Cardiovasc Diabetol; 2011 Nov; 10():102. PubMed ID: 22104275
[TBL] [Abstract][Full Text] [Related]
14. [Field, a randomized clinical trial of cardiovascular prevention with fenofibrate in type 2 diabetes].
Radermecker RP; Scheen AJ
Rev Med Liege; 2005 Dec; 60(12):957-61. PubMed ID: 16457397
[TBL] [Abstract][Full Text] [Related]
15. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study.
Ting RD; Keech AC; Drury PL; Donoghoe MW; Hedley J; Jenkins AJ; Davis TM; Lehto S; Celermajer D; Simes RJ; Rajamani K; Stanton K;
Diabetes Care; 2012 Feb; 35(2):218-25. PubMed ID: 22210576
[TBL] [Abstract][Full Text] [Related]
16. Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.
Keating GM
Am J Cardiovasc Drugs; 2011 Aug; 11(4):227-47. PubMed ID: 21675801
[TBL] [Abstract][Full Text] [Related]
17. Uric acid predicts long-term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD study.
Cao JY; Waldman B; O'Connell R; Sullivan DR; Scott RS; Aryal N; Gebski V; Marschner I; Taskinen MR; Simes JR; McGill N; Jenkins AJ; Keech AC;
Diabetes Obes Metab; 2020 Aug; 22(8):1388-1396. PubMed ID: 32243036
[TBL] [Abstract][Full Text] [Related]
18. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study.
Lancet; 2001 Mar; 357(9260):905-10. PubMed ID: 11289345
[TBL] [Abstract][Full Text] [Related]
19. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].
Scott R; Best J; Forder P; Taskinen MR; Simes J; Barter P; Keech A;
Cardiovasc Diabetol; 2005 Aug; 4():13. PubMed ID: 16111499
[TBL] [Abstract][Full Text] [Related]
20. Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.
Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group
Diabetes Care; 2016 Jul; 39(7):1089-100. PubMed ID: 27289122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
